

The 2023-2028 Outlook for Non-Hodgkin Lymphoma Chemotherapy Therapeutics in China

https://marketpublishers.com/r/2136F8112028EN.html

Date: August 2022 Pages: 190 Price: US\$ 595.00 (Single User License) ID: 2136F8112028EN

Abstracts

This study covers the latent demand outlook for non-Hodgkin lymphoma chemotherapy therapeutics across the regions of China, including provinces, autonomous regions (Guangxi, Nei Mongol, Ningxia, Xinjiang, Xizang - Tibet), municipalities (Beijing, Chongqing, Shanghai, and Tianjin), special administrative regions (Hong Kong and Macau), and Taiwan (all hereafter referred to as 'regions'). Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 1,100 cities in China. For each major city in question, the percent share the city is of the region and of China is reported. Each major city is defined as an area of 'economic population', as opposed to the demographic population within a legal geographic boundary. For many cities, the economic population is much larger that the population within the city limits; this is especially true for the cities of the Western regions. For the coastal regions, cities which are close to other major cities or which represent, by themselves, a high percent of the regional population, actual city-level population is closer to the economic population (e.g. in Beijing). Based on this 'economic' definition of population, comparative benchmarks allow the reader to quickly gauge a city's marketing and distribution value vis-?-vis others. This exercise is quite useful for persons setting up distribution centers or sales force strategies. Using econometric models which project fundamental economic dynamics within each region and city of influence, latent demand estimates are created for non-Hodgkin lymphoma chemotherapy therapeutics. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved.

In this report we define the sales of non-Hodgkin lymphoma chemotherapy therapeutics



as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Bayer, Bristol-Myers Squibb, F. Hoffmann-La Roche, GlaxoSmithKline, Merck & Company, Novartis International, and Pfizer. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022).



Contents

1 INTRODUCTION

1.1 OVERVIEW
1.2 WHAT IS LATENT DEMAND AND THE P.I.E.?
1.3 THE METHODOLOGY
1.3.1 STEP 1. PRODUCT DEFINITION AND DATA COLLECTION
1.3.2 STEP 2. FILTERING AND SMOOTHING
1.3.3 STEP 3. FILLING IN MISSING VALUES
1.3.4 STEP 4. VARYING PARAMETER, NON-LINEAR ESTIMATION
1.3.5 STEP 5. FIXED-PARAMETER LINEAR ESTIMATION
1.3.6 STEP 6. AGGREGATION AND BENCHMARKING
1.4 FREQUENTLY ASKED QUESTIONS (FAQ)
1.4.1 CATEGORY DEFINITION
1.4.2 UNITS
1.4.3 METHODOLOGY

2 SUMMARY OF FINDINGS

- 2.1 LATENT DEMAND IN CHINA
- 2.2 TOP 100 CITIES SORTED BY RANK
- 2.3 LATENT DEMAND BY YEAR IN CHINA

3 ANHUI

- 3.1 LATENT DEMAND BY YEAR ANHUI
- 3.2 CITIES SORTED BY RANK ANHUI
- 3.3 CITIES SORTED ALPHABETICALLY ANHUI

4 BEIJING

4.1 LATENT DEMAND BY YEAR - BEIJING4.2 CITIES SORTED BY RANK - BEIJING4.3 CITIES SORTED ALPHABETICALLY - BEIJING

5 CHONGQING

5.1 LATENT DEMAND BY YEAR - CHONGQING

The 2023-2028 Outlook for Non-Hodgkin Lymphoma Chemotherapy Therapeutics in China



5.2 CITIES SORTED BY RANK - CHONGQING 5.3 CITIES SORTED ALPHABETICALLY - CHONGQING

6 FUJIAN

6.1 LATENT DEMAND BY YEAR - FUJIAN6.2 CITIES SORTED BY RANK - FUJIAN6.3 CITIES SORTED ALPHABETICALLY - FUJIAN

7 GANSU

7.1 LATENT DEMAND BY YEAR - GANSU7.2 CITIES SORTED BY RANK - GANSU7.3 CITIES SORTED ALPHABETICALLY - GANSU

8 GUANGDONG

8.1 LATENT DEMAND BY YEAR - GUANGDONG8.2 CITIES SORTED BY RANK - GUANGDONG8.3 CITIES SORTED ALPHABETICALLY - GUANGDONG

9 GUANGXI

9.1 LATENT DEMAND BY YEAR - GUANGXI9.2 CITIES SORTED BY RANK - GUANGXI9.3 CITIES SORTED ALPHABETICALLY - GUANGXI

10 GUIZHOU

10.1 LATENT DEMAND BY YEAR - GUIZHOU10.2 CITIES SORTED BY RANK - GUIZHOU10.3 CITIES SORTED ALPHABETICALLY - GUIZHOU

11 HAINAN

11.1 LATENT DEMAND BY YEAR - HAINAN11.2 CITIES SORTED BY RANK - HAINAN11.3 CITIES SORTED ALPHABETICALLY - HAINAN



12 HEBEI

12.1 LATENT DEMAND BY YEAR - HEBEI12.2 CITIES SORTED BY RANK - HEBEI12.3 CITIES SORTED ALPHABETICALLY - HEBEI

13 HEILONGJIANG

13.1 LATENT DEMAND BY YEAR - HEILONGJIANG13.2 CITIES SORTED BY RANK - HEILONGJIANG13.3 CITIES SORTED ALPHABETICALLY - HEILONGJIANG

14 HENAN

14.1 LATENT DEMAND BY YEAR - HENAN14.2 CITIES SORTED BY RANK - HENAN14.3 CITIES SORTED ALPHABETICALLY - HENAN

15 HONG KONG

15.1 LATENT DEMAND BY YEAR - HONG KONG15.2 CITIES SORTED BY RANK - HONG KONG15.3 CITIES SORTED ALPHABETICALLY - HONG KONG

16 HUBEI

16.1 LATENT DEMAND BY YEAR - HUBEI16.2 CITIES SORTED BY RANK - HUBEI16.3 CITIES SORTED ALPHABETICALLY - HUBEI

17 HUNAN

17.1 LATENT DEMAND BY YEAR - HUNAN17.2 CITIES SORTED BY RANK - HUNAN17.3 CITIES SORTED ALPHABETICALLY - HUNAN

18 JIANGSU

18.1 LATENT DEMAND BY YEAR - JIANGSU



18.2 CITIES SORTED BY RANK - JIANGSU18.3 CITIES SORTED ALPHABETICALLY - JIANGSU

19 JIANGXI

19.1 LATENT DEMAND BY YEAR - JIANGXI19.2 CITIES SORTED BY RANK - JIANGXI19.3 CITIES SORTED ALPHABETICALLY - JIANGXI

20 JILIN

20.1 LATENT DEMAND BY YEAR - JILIN20.2 CITIES SORTED BY RANK - JILIN20.3 CITIES SORTED ALPHABETICALLY - JILIN

21 LIAONING

21.1 LATENT DEMAND BY YEAR - LIAONING21.2 CITIES SORTED BY RANK - LIAONING21.3 CITIES SORTED ALPHABETICALLY - LIAONING

22 MACAU

22.1 LATENT DEMAND BY YEAR - MACAU22.2 CITIES SORTED BY RANK - MACAU22.3 CITIES SORTED ALPHABETICALLY - MACAU

23 NEI MONGGOL

23.1 LATENT DEMAND BY YEAR - NEI MONGGOL23.2 CITIES SORTED BY RANK - NEI MONGGOL23.3 CITIES SORTED ALPHABETICALLY - NEI MONGGOL

24 NINGXIA

24.1 LATENT DEMAND BY YEAR - NINGXIA24.2 CITIES SORTED BY RANK - NINGXIA24.3 CITIES SORTED ALPHABETICALLY - NINGXIA



25 QINGHAI

25.1 LATENT DEMAND BY YEAR - QINGHAI25.2 CITIES SORTED BY RANK - QINGHAI25.3 CITIES SORTED ALPHABETICALLY - QINGHAI

26 SHAANXI

26.1 LATENT DEMAND BY YEAR - SHAANXI26.2 CITIES SORTED BY RANK - SHAANXI26.3 CITIES SORTED ALPHABETICALLY - SHAANXI

27 SHANDONG

27.1 LATENT DEMAND BY YEAR - SHANDONG27.2 CITIES SORTED BY RANK - SHANDONG27.3 CITIES SORTED ALPHABETICALLY - SHANDONG

28 SHANGHAI

28.1 LATENT DEMAND BY YEAR - SHANGHAI28.2 CITIES SORTED BY RANK - SHANGHAI28.3 CITIES SORTED ALPHABETICALLY - SHANGHAI

29 SHANXI

29.1 LATENT DEMAND BY YEAR - SHANXI29.2 CITIES SORTED BY RANK - SHANXI29.3 CITIES SORTED ALPHABETICALLY - SHANXI

30 SICHUAN

30.1 LATENT DEMAND BY YEAR - SICHUAN30.2 CITIES SORTED BY RANK - SICHUAN30.3 CITIES SORTED ALPHABETICALLY - SICHUAN

31 TAIWAN

31.1 LATENT DEMAND BY YEAR - TAIWAN



31.2 CITIES SORTED BY RANK - TAIWAN 31.3 CITIES SORTED ALPHABETICALLY - TAIWAN

32 TIANJIN

32.1 LATENT DEMAND BY YEAR - TIANJIN32.2 CITIES SORTED BY RANK - TIANJIN32.3 CITIES SORTED ALPHABETICALLY - TIANJIN

33 XINJIANG UYGUR

33.1 LATENT DEMAND BY YEAR - XINJIANG UYGUR33.2 CITIES SORTED BY RANK - XINJIANG UYGUR33.3 CITIES SORTED ALPHABETICALLY - XINJIANG UYGUR

34 XIZANG [TIBET]

34.1 LATENT DEMAND BY YEAR - XIZANG [TIBET]34.2 CITIES SORTED BY RANK - XIZANG [TIBET]34.3 CITIES SORTED ALPHABETICALLY - XIZANG [TIBET]

35 YUNNAN

35.1 LATENT DEMAND BY YEAR - YUNNAN35.2 CITIES SORTED BY RANK - YUNNAN35.3 CITIES SORTED ALPHABETICALLY - YUNNAN

36 ZHEJIANG

36.1 LATENT DEMAND BY YEAR - ZHEJIANG36.2 CITIES SORTED BY RANK - ZHEJIANG36.3 CITIES SORTED ALPHABETICALLY - ZHEJIANG

37 DISCLAIMERS, WARRANTIES, AND USER AGREEMENT PROVISIONS

37.1 DISCLAIMERS & SAFE HARBOR 37.2 ICON GROUP INTERNATIONAL, INC. USER AGREEMENT PROVISIONS



I would like to order

Product name: The 2023-2028 Outlook for Non-Hodgkin Lymphoma Chemotherapy Therapeutics in China

Product link: https://marketpublishers.com/r/2136F8112028EN.html

Price: US\$ 595.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/2136F8112028EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

**All fields are required

Custumer signature _

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970



The 2023-2028 Outlook for Non-Hodgkin Lymphoma Chemotherapy Therapeutics in China